Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nicopholine SCHEMBL11483977 | 1.00 | PKM (0.61) | PKMMAPK1MEN1KMT2APOLB | |
| Nicopholine SCHEMBL967933 | 1.00 | PKM (0.61) | PKMMAPK1MEN1KMT2APOLB | |
| SCHEMBL31699695 | 0.94 | ALDH1A1 (0.56) | PKMMAPK1MEN1KMT2APOLB | |
| SCHEMBL27857429 | 0.90 | HPGD (0.71) | PKMMAPK1MEN1KMT2APOLB | |
| SCHEMBL9763711 | 0.88 | PKM (0.74) | PKMMAPK1MEN1KMT2APOLB | |
| Hydrochloric Acid SCHEMBL1596692 | 0.86 | PKM (0.72) | PKMMAPK1MEN1KMT2APOLB | |
| SCHEMBL29457007 | 0.85 | PKM (0.66) | PKMMAPK1MEN1KMT2APOLB | |
| SCHEMBL6640482 | 0.85 | PKM (0.66) | PKMMAPK1MEN1KMT2APOLB | |
| SCHEMBL22702163 | 0.85 | PKM (0.66) | PKMMAPK1MEN1KMT2APOLB | |
| SCHEMBL25653364 | 0.84 | MKNK1 (0.71) | MEN1KMT2AMAPTHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085064-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | KARYOPHARM THERAPEUTICS INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-12583851-B2 | Heteroaryl-substituted pyrazine derivatives as pesticides | ELANCO ANIMAL HEALTH GMBH (DE) | 2026-03-24 | — | — | US | disclosed |
| US-12331040-B2 | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | Karyopharm Therapeutics Inc. (US) | 2025-06-17 | — | — | US | disclosed |
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2025-03-20 | — | — | US | disclosed |
| US-20230023326-A1 | HETEROARYL-SUBSTITUTED PYRAZINE DERIVATIVES AS PESTICIDES | ELANCO ANIMAL HEALTH GMBH (DE) | 2023-01-26 | — | — | US | disclosed |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2022-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583851-B2 | Heteroaryl-substituted pyrazine derivatives as pesticides | CBR3, CYCS, CWC15 | PKM 3610/4885MAPK1 3695/4885MEN1 4368/4885 |
| US-20230023326-A1 | HETEROARYL-SUBSTITUTED PYRAZINE DERIVATIVES AS PESTICIDES | DDT, PRXL2A, CAT | PKM 1516/4885MAPK1 4120/4885MEN1 3892/4885 |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DCK, CDC7, DNMT1 | PKM 2323/4885MAPK1 1307/4885MEN1 964/4885 |
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | BRAF, RAF1, NRAS | PKM 4478/4885MAPK1 140/4885MEN1 1712/4885 |
| US-12331040-B2 | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | BCL6, MALT1, BTK | PKM 1025/4885MAPK1 3064/4885MEN1 1533/4885 |
| US-20260085064-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | BCL6, MALT1, BCL6B | PKM 2135/4885MAPK1 3250/4885MEN1 783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.